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Summary objective To compare two commercially available kits, Japanese Encephalitis-Dengue IgM Combo
ELISA (Panbio Diagnostics) and JEV-CheX IgM capture ELISA (XCyton Diagnostics Limited), to a
reference standard (Universiti Malaysia Sarawak – Venture Technologies VT ELISA).
methods Samples were obtained from 172 ⁄ 192 children presenting to a site in rural India with acute
encephalitis syndrome.
results Using the reference VT ELISA, infection with Japanese encephalitis virus (JEV) was confirmed
in 44 (26%) patients, with central nervous system infection confirmed in 27 of these; seven patients were
dengue seropositive. Of the 121 remaining patients, 37 (31%) were JEV negative and 84 (69%) were
JEV unknown because timing of the last sample tested was <10 day of illness or unknown. For patient
classification with XCyton, using cerebrospinal fluid alone (the recommended sample), sensitivity was
77.8% (59.2–89.4) with specificity of 97.3% (90.6–99.2). For Panbio ELISA, using serum alone (the
recommended sample), sensitivity was 72.5% (57.2–83.9) with specificity of 97.5% (92.8–99.1). Using
all available samples for patient classification, sensitivity and specificity were 63.6% (95% CI: 48.9–
76.2) and 98.4% (94.5–99.6), respectively, for XCyton ELISA and 75.0% (59.3–85.4) and 97.7%
(93.3–99.2) for Panbio ELISA.
conclusion The two commercially available ELISAs had reasonable sensitivities and excellent spec-
ificities for diagnosing JEV.
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Introduction
Japanese encephalitis virus (JEV) is a mosquito-borne
flavivirus; it is the leading cause of encephalitis in South-
east Asia. Over 3 billion people live in areas where
Japanese encephalitis (JE) is endemic; it causes an esti-
mated 20 000–175 000 cases annually with 6000–15 000
deaths (Tsai 2000; Halstead & Tsai 2004; Ghosh & Basu
2009). The virus continues to spread into new areas and
often co-circulates with the related flavivirus, dengue.
Affordable vaccines are now becoming available, but
implementation programmes are hampered because the
epidemiological data and surveillance for JE are poor; this
is largely because of lack of standardised diagnostics. JE is
endemic in resource-poor areas and in these settings;
patients often have a clinical diagnosis only. Serological
tests are the gold standard for diagnosis of JEV as the
period of viraemia is short, making methods to detect
genomic material or viral antigen unreliable (WHO 2006).
The timing of sample collection and type of sample
collected impact on the ability to confirm the diagnosis of
JEV. Cerebrospinal fluid (CSF) is the sample of choice, as
detection of antibodies in the CSF confirms viral infection
of the central nervous system (CNS). Serum samples
demonstrate recent peripheral infection only. Even dem-
onstrating a rising serum IgM is insufficient for confirma-
tion of JEV as the causative agent for an acute encephalitis
syndrome (AES), as this does not distinguish peripheral
from CNS infection. Studies from Thailand suggest that
high titres of JEV IgM may be found in sera of asymp-
tomatic individuals (Grossman et al. 1973). Burke et al.
(1985) found that by day 7 of illness, 100% of patients
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